Investigational drug · Phase 3
Vicadrostat
Also called: BI 690517
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Heart Failure, Diabetes Mellitus, Type 2, Hypertension.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
4 still active
All registered trials
20
Any phase or sponsor naming "Vicadrostat"
First trial start
2024
Jun 17, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Vicadrostat", any sponsor or status.
- Phase 112
Conditions studied
As listed on its trial records.
- Heart Failure
- Diabetes Mellitus, Type 2
- Hypertension
- Cardiovascular Diseases
- Kidney Disease, Chronic
- Chronic Kidney Disease
Approved drugs for the same conditions: High blood pressure (hypertension) · Heart failure · Chronic kidney disease · Cardiovascular and metabolic · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Vicadrostat" as an intervention, largest first.
- EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseasePivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07064473 · 11,800 participants (planned) · Start Jul 22, 2025 · Primary completion Dec 14, 2029
Drug: Vicadrostat; Empagliflozin and 1 more · For: Diabetes Mellitus, Type 2; Hypertension; Cardiovascular Diseases
Sites: Anniston, Alabama; Fairhope, Alabama; Guntersville, Alabama · 1,142 sites in all
- EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)Pivotal-lookingActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06531824 · 8,371 participants · Start Aug 30, 2024 · Primary completion Dec 31, 2026
Drug: BI 690517; Placebo matching BI 690517 and 1 more · For: Kidney Disease, Chronic
Sites: Huntsville, Alabama; Surprise, Arizona; Beverly Hills, California · 562 sites in all
- A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart FailurePivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06424288 · 6,712 participants (planned) · Start Jun 17, 2024 · Primary completion May 22, 2028
Drug: vicadrostat; empagliflozin and 1 more · For: Heart Failure
Sites: Mobile, Alabama; Chula Vista, California; Orange, California · 672 sites in all
- A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the HeartPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06935370 · 4,200 participants (planned) · Start May 20, 2025 · Primary completion Feb 4, 2029
Drug: vicadrostat; empagliflozin and 1 more · For: Heart Failure
Sites: Beverly Hills, California; Covina, California; Encinitas, California · 596 sites in all
- A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney DiseasePivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT05182840 · 714 participants · Start Jan 11, 2022 · Primary completion Jun 19, 2023
Drug: BI 690517; Placebo to BI 690517 and 2 more · For: Kidney Disease, Chronic
Sites: Mesa, Arizona; Phoenix, Arizona; Canyon Country, California · 203 sites in all
- A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney DiseasePivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT06926660 · 492 participants · Start Jul 18, 2025 · Primary completion Aug 14, 2026
Drug: Vicadrostat; Empagliflozin and 1 more · For: Chronic Kidney Disease
Sites: Huntsville, Alabama; Anaheim, California; San Dimas, California · 157 sites in all
- This Will be a Randomized Comparison of the Proteomic Effects of Vicadrostat/Empagliflozin Versus Empagliflozin and Versus Empagliflozin/Spironolactone in Heart Failure Patients With Preserved Ejection FractionPivotal-lookingNot yet recruiting
Baim Institute for Clinical ResearchAcademic, hospital or other
NCT07857772 · 200 participants (planned) · Start Mar 2027 · Primary completion May 2028
Drug: empa plus vica; Comparator: empa 10 plus spironolactone · For: Heart Failure With Preserved Ejection Fraction (HFPEF)
- Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)Pivotal-lookingRecruiting
University Medical Center GroningenAcademic, hospital or other
NCT07304817 · 100 participants (planned) · Start May 12, 2026 · Primary completion Feb 2028
Drug: vicadrostat / empagliflozin combination 1; Spironolactone (drug) · For: CKD; Cardiovascular Diseases; Heart Failure
Sites: Groningen, Netherlands · 2 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT03100916 · 72 participants · Start May 5, 2017 · Primary completion Nov 24, 2017
Drug: BI 690517; Placebo and 2 more · For: Healthy
Sites: Mannheim, Germany
Boehringer IngelheimBoehringer Ingelheim
NCT03165240 · 62 participants · Start Oct 5, 2017 · Primary completion Apr 16, 2020
Drug: BI 690517; Eplerenone and 1 more · For: Diabetic Nephropathies
Sites: Gentofte Municipality, Denmark; Kolding, Denmark; København NV, Denmark · 40 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Aldosterone synthase inhibition for treatment of people with chronic kidney disease.
Tuttle KR, Trbojevic-Stankovic JB, Alicic RZ, et al. · Clin Kidney J 2026
- Aldosterone synthase inhibitors: biological rationale, mechanism of action, and results of clinical trials.
Surma S, Narkiewicz K · Am J Hypertens 2026
- Efficacy and safety of selective aldosterone synthase inhibitors for blood pressure reduction in patients with CKD: a meta-analysis of randomized controlled trials.
Theodorakopoulou M, Iatridi F, Theodosiadi A, et al. · J Hypertens 2026
- Aldosterone Synthase Inhibitors: Emerging Therapeutic Strategies in Resistant Hypertension.
Pradhan A, Bhandari M, Singh A, et al. · Life (Basel) 2026
- Pharmacokinetics of novel drugs for the treatment of diabetic nephropathy.
Mousavi T, Shaya FT, Munir KM, et al. · Expert Opin Drug Metab Toxicol 2026
- New Drugs on the Horizon for Hypertension.
Jackson GG, Luther JM, Alexander MR · Adv Kidney Dis Health 2026
Also in development for Heart Failure
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- IRP101meta-fluorobenzylguanidine, 18F-MFBGPhase 34 trials
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) · Cardiovascular Diseases, Heart Failure, Ischemic Cardiomyopathy
- ZiltivekimabPhase 34 trials
Novo Nordisk · Acute Myocardial Infarction (AMI), Myocardial Infarction, Heart Failure
- HiCM-188 therapyPhase 32 trials
HELP Therapeutics Co., Ltd. · Heart Failure
- Qishen Yiqi Dripping Pills 2 bagsPhase 32 trials
Tasly Pharmaceutical Group Co., Ltd · Heart Failure, Chronic Heart Failure With Preserved Ejection Fraction
- IMR-687Tovinontrine, CRD-750Phase 23 trials
Cardurion Pharmaceuticals, Inc. · Heart Failure, Cardiovascular Diseases, Heart Diseases
- CDR132LPhase 22 trials
Novo Nordisk · Heart Failure
- AZD3427Phase 21 trial
AstraZeneca · Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Boehringer Ingelheim.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.